Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Pediatr Transplant ; 10(4): 497-500, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16712610

RESUMO

Treatment of severe aplastic anemia (SAA) patients who lack human leukocyte antigen (HLA)-matched donors and failed immunosuppressive therapy (IST) is challenging. Recently, umbilical cord blood transplantation (CBT) after non-myeloablative therapy has been reported in adult but not in childhood SAA. However, most cases resulted in mixed donor chimerism and incomplete hematological recovery. We reported an 11-yr-old girl with recurred SAA 5 yr after IST who underwent unrelated donor CBT after a modified regimen. This patient had renal and cardiac dysfunction, and lacked suitable bone marrow donors. The 3.9 x 10(7)/kg CB cells from an HLA one-locus mismatched unrelated donor were infused after conditioning with total body irradiation (5 Gy), melphalan (120 mg/m(2)), and fludarabin (120 mg/m(2)). Hematological recovery was favorable in complete chimerism. A major complication was only skin graft-versus-host disease (grade I). CB could be an alternate stem cell source for childhood SAA after modified preparative regimen.


Assuntos
Anemia Aplástica/terapia , Transplante de Células-Tronco de Sangue do Cordão Umbilical , Histocompatibilidade , Condicionamento Pré-Transplante , Criança , Transplante de Células-Tronco de Sangue do Cordão Umbilical/métodos , Feminino , Seguimentos , Glucocorticoides/administração & dosagem , Doença Enxerto-Hospedeiro/tratamento farmacológico , Teste de Histocompatibilidade , Humanos , Melfalan/administração & dosagem , Agonistas Mieloablativos/administração & dosagem , Prednisolona/administração & dosagem , Índice de Gravidade de Doença , Fatores de Tempo , Quimeras de Transplante , Resultado do Tratamento , Vidarabina/administração & dosagem , Vidarabina/análogos & derivados , Irradiação Corporal Total/métodos
3.
Support Care Cancer ; 14(2): 153-60, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15999262

RESUMO

BACKGROUND: Peripherally inserted central venous catheters (PICCs) have been increasingly used in pediatric patients. However, little is known about the incidence and risk of complications when using this device in children with cancer. The purposes of this study are to assess the feasibility of PICCs and to determine the risk factors for PICC-related complications in pediatric patients with various types of malignancies. PATIENTS AND METHODS: We attempted to place PICCs in 53 patients with a median age of 5 years ranging from 2 months to 20 years. PICCs were used to administer fluid, parenteral nutrition, anticancer agents, antibiotics, and blood products and also for the through-line blood sampling. The duration of catheterization and the incidence of PICC-related complications requiring removal were retrospectively evaluated in association with the diagnosis, sex, age and body weight of the patients, size, insertion site and tip location of the catheters, type of treatment, and duration of leukopenia. RESULTS: PICCs were successfully placed in 109 of 112 attempts (97.3%) in 53 patients, and they were followed for a total of 11,797 catheter days (median placement, 87 days; range, 3 to 512 days). Fifty five PICCs (50.5%) were removed as a result of PICC-related complications with a rate of 4.66 per 1,000 catheter days. The most common reasons for catheter removal were occlusion (n=18), breakage/leakage (15), and infection (10). More than 70% of such complications occurred more than 30 days after placement. The catheter tip location in the superior vena cava or the right atrium might decrease the risk of complications. Other parameters did not influence the incidence of complications. CONCLUSIONS: PICCs were found to provide a reliable access for prolonged intravenous administration and blood sampling in children intensively treated for hematologic and solid malignancies, thus leading to a reduction of physical pain and psychological stress in such patients. However, the long-term placement of PICCs may also be related to an increased risk of complications.


Assuntos
Cateterismo Venoso Central/efeitos adversos , Adolescente , Adulto , Antineoplásicos/administração & dosagem , Criança , Pré-Escolar , Feminino , Seguimentos , Testes Hematológicos , Humanos , Incidência , Lactente , Infusões Intravenosas , Masculino , Neoplasias/tratamento farmacológico , Estudos Retrospectivos , Fatores de Risco
4.
Pediatr Blood Cancer ; 47(1): 103-6, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16047346

RESUMO

We report a case of juvenile xanthogranuloma (JXG) having progressive pancytopenia for 6 months until the proliferating skin lesions. A 2-month-old infant presented recurrent fever, anemia, and hepatosplenomegaly mimicking hemophagocytic lymphohistiocytosis (HLH) or juvenile myelomonocytic leukemia (JMML). At 8 months of age, the biopsy of a growing papule on the elbow made the diagnosis. Bone marrow (BM) specimens showed clustering foamy cells including hemophagocytosis by histiocytes. Treatment with etoposide followed by vinblastine plus prednisolone (PSL) therapy improved the disease. Although JXG is a benign non-Langerhans cell histiocytosis, the multisystem-visceral form should be considered as a potential aggressive disease when associated with BM failure in early infancy.


Assuntos
Pancitopenia/etiologia , Xantogranuloma Juvenil/complicações , Xantogranuloma Juvenil/patologia , Transtornos da Coagulação Sanguínea/etiologia , Medula Óssea/patologia , Hepatomegalia/etiologia , Humanos , Lactente , Masculino , Esplenomegalia/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...